PT  - JOURNAL ARTICLE
AU  - Rini, Brian I.
AU  - McDermott, David F.
AU  - Hammers, Hans
AU  - Bro, William
AU  - Bukowski, Ronald M.
AU  - Faba, Bernard
AU  - Faba, Jo
AU  - Figlin, Robert A.
AU  - Hutson, Thomas
AU  - Jonasch, Eric
AU  - Joseph, Richard W.
AU  - Leibovich, Bradley C.
AU  - Olencki, Thomas
AU  - Pantuck, Allan J.
AU  - Quinn, David I.
AU  - Seery, Virginia
AU  - Voss, Martin H.
AU  - Wood, Christopher G.
AU  - Wood, Laura S.
AU  - Atkins, Michael B.
TI  - Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
AID  - 10.1186/s40425-016-0180-7
DP  - 2016 Dec 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - 81
VI  - 4
IP  - 1
4099  - http://jitc.bmj.com/content/4/1/81.short
4100  - http://jitc.bmj.com/content/4/1/81.full
SO  - J Immunother Cancer2016 Dec 01; 4
AB  - Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number of new agents have been approved for RCC, several of which attack tumor angiogenesis by inhibiting vascular endothelial growth factors (VEGF) and VEGF receptors (VEGFR), as well as tumor metabolism, inhibiting the mammalian target of rapamycin (mTOR). Additionally, a new class of immunotherapy agents, immune checkpoint inhibitors, is emerging and will play a significant role in the treatment of patients with RCC. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a Task Force, which met to consider the current role of approved immunotherapy agents in RCC, to provide guidance to practicing clinicians by developing consensus recommendations and to set the stage for future immunotherapeutic developments in RCC.Abbreviations:CNSCentral nervous systemCRComplete responseCWGCytokine working groupDFSDisease-free survivalECOGEastern Cooperative Oncology GroupFDAU.S. Food and Drug AdministrationHD IL-2High dose interleukin-2IFNInterferon-alphaIL-2Interleukin-2mRCCMetastatic RCCMSKCCMemorial-Sloan Kettering Cancer CentermTORMammalian target of rapamycinORROverall response rateOSOverall survivalPD-1Programmed death receptor 1PD-L1Programmed death ligand 1PRPartial responseRCCMetastatic renal cell cancerRFSRecurrence-free survivalSDStable diseaseSITCSociety for immunotherapy of cancerSQSubcutaneousTKITyrosine kinase inhibitorVEGFVascular endothelial growth factorVEGFRVascular endothelial growth factor receptor